United Therapeutics Corporation (UTHR) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

United Therapeutics Corporation (UTHR) closed at USD 540.03 on 2026-10-14, a change of +30 % over the past year, with a market capitalization of USD 23.23B.

United Therapeutics Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

United Therapeutics Corporation key figures

Previous close

USD 540.03 (2026-10-14)

1-year change

+30 %

Market cap

USD 23.23B

Enterprise value

USD 20.56B

P/E ratio (trailing)

19.40

P/E ratio (forward)

17.81

EPS (trailing)

27.92

EPS (forward)

30.41

PEG ratio

2.22

Price to book

3.61

Revenue growth

-1.9 %

Earnings growth

13.4 %

Dividend per share (trailing)

0.00

Short ratio

4.18

Employees

1,400

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for United Therapeutics Corporation and compare it with other stocks.